NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC

NDA Filingsacituzumab tirumotecanPositive

AI Analysis

Summary

Sichuan Kelun-Biotech announced that the NMPA has accepted a new indication application for sacituzumab tirumotecan (sac-TMT) as a first-line treatment for advanced triple-negative breast cancer, a TROP2-directed antibody drug conjugate.

Outcome Details

NMPA accepts new indication application

Importance:6/10

Sentiment:

0.70

regulatoryNMPAADCTROP2oncologyTNBCnew indication

Related Companies

$SKBBY

Read the original article

Published by PR Newswire Biotech on July 30, 2026 9:09 AM

Read Original